- Home
- PTA vs EVO Comparison
PTA vs EVO Comparison
Compare PTA & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTA | EVO |
|---|---|---|
| Founded | 2020 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 934.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PTA | EVO |
|---|---|---|
| Price | $19.29 | $3.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 126.5K | 107.1K |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.13 | $2.31 |
| 52 Week High | $20.92 | $4.80 |
Technical Indicators
Market Signals| Indicator | PTA | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 51.88 |
| Support Level | $19.02 | $2.87 |
| Resistance Level | $19.74 | $3.78 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 44.54 | 50.00 |
Price Performance
Historical ComparisonAbout PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.